PNAS 研究:太空培养的胶质母细胞瘤类器官更接近晚期肿瘤特征
Space-grown glioblastoma organoids could help advance brain cancer treatments
美国圣母大学 Meenal Datta 团队在国际空间站培养胶质母细胞瘤与先天免疫细胞的三维类器官 40 天后返回地面分析,发现炎症、免疫应答、组织重塑和血管生成相关基因更活跃,与侵袭性 GBM 相关的蛋白水平更高,免疫抑制性微环境也更明显。该结果发表于 PNAS,团队称其产出了首个来自太空培养类器官的综合多组学数据集。团队已启动两项后续国际空间站研究,使用患者来源的 GBM-免疫类器官。
研究对比太空微重力与地面培养的胶质母细胞瘤类器官,为构建更接近人肿瘤的模型提供了一条可迁移路径。
by International Space Station U.S. National Laboratory
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and is one of the most aggressive and deadly forms of cancer. It is difficult for surgeons to fully remove GBM because it often has microscopic "tentacles" that extend from the tumor into healthy brain tissue. GBM is also hard to treat because it creates an immunosuppressive microenvironment that helps the cancer evade immune attack and resist therapy.
To improve treatments, scientists must better understand the mechanisms involved in this complex disease, but accurately modeling GBM in the laboratory remains a challenge. Even sophisticated models called organoids, designed to mimic the structure and biology of human tumors, fail to fully reproduce key features of advanced GBM. When culturing cells on Earth, gravity causes them to settle, creating conditions that can interfere with the formation of complex 3D structures. That is why a team of researchers at the University of Notre Dame, led by Meenal Datta, took their research to space.
Leveraging the International Space Station (ISS) National Laboratory, the team grew three-dimensional organoids from GBM cells and innate immune cells that more closely replicate the structure and behavior of GBM tumors than organoids grown on Earth. In microgravity, cells can assemble into 3D structures with less interference from sedimentation, allowing researchers to better recreate the tumor architecture and cellular interactions seen in human disease. The results, recently published in PNAS, suggest that space-grown organoids could provide more realistic GBM models for studying cancer progression and testing new therapeutics.
In the investigation, which launched in 2024 with support from ISS National Lab commercial service provider Space Tango, the Notre Dame team grew GBM-immune organoids in space for 40 days before returning them to Earth for analysis. The researchers found that in the space-grown organoids, genes related to inflammation, immune responses, tissue remodeling and blood vessel formation were more active, and the levels of proteins associated with more aggressive GBM biology were higher. Additionally, the space-grown organoids showed a more immunosuppressive tumor microenvironment, a hallmark of advanced GBM that helps tumors resist the body's immune defenses.
Datta said the study also produced the first comprehensive multiomics data set from space-grown organoids, providing insights into gene activity, protein expression and how cells interact and are organized within the tissue.
"By growing GBM organoids on the ISS, we demonstrated that microgravity fuels a model phenotype that recapitulates human tumors better and faster than we achieve on the ground. This work helps lay the foundation for a new era of orbital oncology that moves cancer research from bedside to orbit and back again," said Datta, the Jane Schoelch DeFlorio collegiate professor of aerospace and mechanical engineering at the University of Notre Dame.
To build on these results, Datta and her team have launched two additional ISS investigations using patient-derived GBM-immune organoids, with the most recent flying on the SpaceX CRS-35 mission for NASA. By providing models that more fully capture the complex architecture and biology of advanced tumors, space-grown organoids could help researchers better understand GBM progression and accelerate the development of new therapies for patients on Earth.
"Datta and her team at the Tumor Immune Microenvironment and Mechanics Laboratory brought their expertise in one of the most aggressive and incurable brain cancers to space, where they demonstrated microgravity's unique ability to improve organoid models that function as 'mini tumors.' By combining human-derived glioblastoma cells with immune cells in space, this work could prove to be a landmark study in the effort to better understand and treat GBM and other aggressive cancers," said ISS National Lab chief scientist Michael Roberts.
Publication details
Alice Burchett Darantiere et al., Multi-omics and spatial analysis of microgravity-grown glioblastoma organoids reveal superior modeling of advanced disease after long-term spaceflight, Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2616218123
Journal information: Proceedings of the National Academy of Sciences
Key medical concepts
Clinical categories
Provided by International Space Station U.S. National Laboratory
Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Space-grown glioblastoma organoids could help advance brain cancer treatments (2026, October 30) retrieved 30 October 2026 from https://medicalxpress.com/news/2026-10-space-grown-glioblastoma-organoids-advance.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com